0001104659-19-041021.txt : 20190718 0001104659-19-041021.hdr.sgml : 20190718 20190718190422 ACCESSION NUMBER: 0001104659-19-041021 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190717 FILED AS OF DATE: 20190718 DATE AS OF CHANGE: 20190718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Read Simon CENTRAL INDEX KEY: 0001688199 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37926 FILM NUMBER: 19962153 MAIL ADDRESS: STREET 1: 87 CAMBRIDGEPARK DRIVE STREET 2: C/O RA PHARMACEUTICALS, INC. CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001481512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262908274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 87 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617) 401-4060 MAIL ADDRESS: STREET 1: 87 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 a4.xml 4 X0306 4 2019-07-17 0 0001481512 Ra Pharmaceuticals, Inc. RARX 0001688199 Read Simon C/O RA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 0 1 0 0 Chief Scientific Officer COMMON STOCK 2019-07-17 4 M 0 10000 2.87 A 16234 D COMMON STOCK 2019-07-17 4 S 0 10000 32.9479 D 6234 D Stock Options (Right to buy) 2.87 2019-07-17 4 M 0 10000 0 D 2026-06-16 Common Stock 10000 96142 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $32.57 to $33.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter. /s/ David Lubner, Attorney-in-Fact for Simon Read 2019-07-18